ClinicalTrials.gg
CompletedNCT03925974Updated Mar 12, 2024

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

A Phase 2 interventional study of KN026 10 mg/kg QW and KN026 20 mg/kg Q2W in Gastric/Gastroesophageal Junction Cancer, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open-label, phase 2 study of KN026 in subjects with HER2 expressing gastric/gastroesophageal junction cancer to evaluate efficacy and safety. The subjects will receive KN026 10 mg/kg QW or 20 mg/kg Q2W or 30mg/kg Q3W until progressive disease, unacceptable toxicity or death.

Read the detailed description

The study consists of two arms as HER2 overexpression arm and HER2 expression arm and both arms will receive KN026 treatment.

02

Conditions studied

  • Gastric/Gastroesophageal Junction Cancer
03

In context

Lead sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd is the lead sponsor of 38 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed inform consent form(ICF)
  • Age ≥ 18 years and ≤ 75 years, male or female
  • or cytologically documented advanced gastric/gastroesophageal junction cancer overexpressing: IHC 3+ or IHC 2+ \& ISH+ HER2 expressing: IHC2+ \& ISH- or IHC 1+ \& ISH+
  • Received at least one prior standard therapy
  • At least one evaluable lesion according to (RECISIT) v 1.1
  • (ECOG) performance status of 0 or 1
  • Adequate organ function
  • ≥ 50% (ECHO)
  • Female patients and males with partners of should be using highly effective measures (failure rate of less than 1% per year). Contraception should be continued for a period of 24 weeks after dosing has been completed.
  • Ability to comply with treatment, procedures and pharmacokinetics (PK) sample collection and the required study follow-up procedures

Exclusion criteria

Exclusion Criteria:

  • Accepted any other anti-tumor drug therapies within 4 weeks before fist dose
  • Accepted radiotherapy within 4 weeks before enrollment
  • An anthracyclines antibiotic treatment was received exceeding 320 mg/m² or other equivalent dose antharcyclines
  • Subjects are eligible with clinically controlled and stable neurologic function >= 4 weeks, which is no evidence of CNS disease progression; Subjects with spinal cord compression and cancerous meningitis are not eligible
  • Pregnant or nursing females;or intend pregnancy within this study period or within 6 monthes after the end of this study
  • History of immunodeficiency, including positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation
  • Severe chronic and active infection, need to system antibiosis/antiviral treatment
  • Cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) are not well controlled, and need locally treatment or repeated drainage
  • Even with peripheral or central venous nutritional support, unintentional weight loss ≥5% within 1 month before the first medication
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    HER2 overexpression

    HER2 IHC 3+ or IHC2+ and ISH+

    Drug: KN026 10 mg/kg QW · Drug: KN026 20 mg/kg Q2W · Drug: KN026 30 mg/kg Q3W

  • Experimental
    HER2 expression

    HER2 IHC 2+ISH- or IHC 1+ and ISH+

    Drug: KN026 10 mg/kg QW · Drug: KN026 20 mg/kg Q2W · Drug: KN026 30 mg/kg Q3W

Interventions

  • DrugKN026 10 mg/kg QW

    Drug page: Anbenitamab

    10 mg/kg QW as safety run-in dosage

  • DrugKN026 20 mg/kg Q2W

    Drug page: Anbenitamab

    20 mg/kg Q2W as target dosage

  • DrugKN026 30 mg/kg Q3W

    Drug page: Anbenitamab

    30 mg/kg Q3W as another target dosage

06

What researchers measure

Primary outcomes

  1. ORR

    clinical response rate (ORR) as determined by investigators based on RECIST 1.1 criteria

    Time frame: 1 years

  2. DOR

    clinical response time (DOR) as determined by investigators based on RECIST 1.1 criteria

    Time frame: 1 years

07

Study locations

1 site
  • 307 Hospital of PLA
    Beijing, Beijing 100071, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2019 to primary completion in May 2022, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2019
First posted
Apr 24, 2019
StartActual
Jun 17, 2019
Primary completionActual
May 31, 2022
CompletionActual
May 31, 2022
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03925974
Responsible party
Sponsor
First posted
Apr 24, 2019
Start date
Jun 17, 2019
Primary completion
May 31, 2022
Completion
May 31, 2022
Last update
Mar 12, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anbenitamab

Start the discussion